Las Vegas—The FDA approval of erenumab-aooe (Aimovig, Amgen/Novartis) presents a “paradigm shift” in managing migraine, given its unique mechanism of activity and its efficacy in mitigating the debilitating effects of this “devastating” chronic condition, according to Dawn C. Buse, PhD, a clinical professor of neurology at Albert Einstein College of Medicine of Yeshiva University, in New York City.
Erenumab-aooe, a self-injected medication, is the